Palbociclib in Combination with either Aromatase Inhibitors or Fulvestrant for Patients with Advanced HR+/HER2- Breast Cancer in Germany: Final Results of the Phase 2 Multicohort INGE-B Trial.
- DOI
- 10.1159/000542459
- Published
- 2025
- Container
- Oncology research and treatment
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1159/000542459,
title = {Palbociclib in Combination with either Aromatase Inhibitors or Fulvestrant for Patients with Advanced HR+/HER2- Breast Cancer in Germany: Final Results of the Phase 2 Multicohort INGE-B Trial.},
author = {Welslau M and Potthoff K and Zaiss M and Müller L and Brucker C and Salat C and Untch M and Meiler J and Lüftner D and Welt A and Dörfel S and Hagen V and Stein A and Liersch R and Kuhn T and Siebenbach HU and Bing G and Vannier C and Marschner N and Gratzke K},
year = {2025},
journal = {Oncology research and treatment},
doi = {10.1159/000542459},
url = {https://doi.org/10.1159/000542459}
}RIS
TY - JOUR TI - Palbociclib in Combination with either Aromatase Inhibitors or Fulvestrant for Patients with Advanced HR+/HER2- Breast Cancer in Germany: Final Results of the Phase 2 Multicohort INGE-B Trial. AU - Welslau M AU - Potthoff K AU - Zaiss M AU - Müller L AU - Brucker C AU - Salat C AU - Untch M AU - Meiler J AU - Lüftner D AU - Welt A AU - Dörfel S AU - Hagen V AU - Stein A AU - Liersch R AU - Kuhn T AU - Siebenbach HU AU - Bing G AU - Vannier C AU - Marschner N AU - Gratzke K PY - 2025 JO - Oncology research and treatment DO - 10.1159/000542459 UR - https://doi.org/10.1159/000542459 ER -
APA
M, W., K, P., M, Z., L, M., C, B., C, S., M, U., J, M., D, L., A, W., S, D., V, H., A, S., R, L., T, K., HU, S., G, B., C, V., N, M., & K, G. (2025). Palbociclib in Combination with either Aromatase Inhibitors or Fulvestrant for Patients with Advanced HR+/HER2- Breast Cancer in Germany: Final Results of the Phase 2 Multicohort INGE-B Trial.. Oncology research and treatment. https://doi.org/10.1159/000542459
Source records
- pubmed · retrieved 2026-09-27T08:43:53.379Z
- europe-pmc · retrieved 2026-09-27T08:43:53.378Z